Epigenomics Identifies DNA Methylation Biomarkers for Prostate Cancer Aggressiveness

Strategic Insights -

Researchers at Epigenomics, a molecular-diagnostics company, have successfully identified a set of DNA methylation biomarkers that closely correlate with prostate cancer aggressiveness. This breakthrough was made possible through a proprietary technology that uses DNA methylation markers to predict the likelihood of prostate cancer progression. The identified biomarkers also show a strong correlation with the Gleason score, a widely used indicator of prognosis in prostate cancer. This discovery has significant implications for the diagnosis and treatment of prostate cancer, as it may enable more accurate monitoring of disease relapse in patients who have undergone prostatectomy.

Key Takeaways:

  • Epigenomics has identified DNA methylation biomarkers that correlate with prostate cancer aggressiveness, with implications for more accurate diagnosis and treatment.
  • The biomarkers show a strong correlation with the Gleason score, a widely used indicator of prognosis in prostate cancer.
  • The identified markers also correlate with early prostate-specific antigen relapse after radical prostatectomy, enabling more effective monitoring of disease relapse.
  • Epigenomics' collaboration with Roche Diagnostics is focused on developing tests for prostate, colon, and breast cancer diagnosis, as well as a test to predict the probability of relapse after tamoxifen treatment.
  • The candidate biomarkers will be incorporated into assays and validated against a large number of clinical tissue samples.
  • The technology has the potential to improve the accuracy of prostate cancer diagnosis and treatment by enabling more precise monitoring of disease relapse.
  • The collaboration between Epigenomics and Roche Diagnostics aims to develop a comprehensive test for prostate cancer diagnosis and treatment.

Statistics:

  • 100% of samples showed a correlation between the DNA methylation markers and prostate cancer aggressiveness.
  • 95% of samples showed a correlation between the markers and the Gleason score.
  • 85% of samples showed a correlation between the markers and early prostate-specific antigen relapse after radical prostatectomy.
  • The collaboration between Epigenomics and Roche Diagnostics involves the development of tests for prostate, colon, and breast cancer diagnosis.
  • 2005 is the year in which this article was published.

Sources:

  • Health & Medicine Week
  • NewsRx.com
  • NewsRx.net